This review highlights the clinical significance of nonobstructive ischemic heart disease in women, its association with left ventricular diastolic dysfunction, and its potential progression to HFpEF.
Answers are grounded in this paper and cite their sources.
Nonobstructive IHD confers high MACE risk in women; challenges prior benign view but leaves management open.
Ischemic heart disease, in the absence of obstructive coronary artery disease, is prevalent in women and constitutes a major risk factor for developing major adverse cardiovascular events, including myocardial infarction, stroke, and heart failure. For decades, diagnosis was considered benign and often minimized; however, it is now known that this etiology carries much risk and is a significant burden to the health care system. This review summarizes the current state of knowledge on nonobstructive ischemic heart disease (NOIHD), the association between NOIHD and left ventricular diastolic dysfunction, potential links between NOIHD and the development of heart failure with preserved ejection fraction (HFpEF), and therapeutic options and knowledge gaps for patients living with NOIHD.
No takes yet. Share an insight, caveat, or question.
Michael D. Nelson (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: